8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

Effective perioperative pain management hinges on multimodal analgesia: combining opioid agonists with non-opioid agents acting at distinct anatomical and molecular targets along the pain pathway. This approach maximizes analgesia while mitigating opioid-induced ventilatory depression, nausea, ileus, and physical dependence.

---

1. Opioid Receptor Classification and Intracellular Signaling

Opioid receptors belong to the rhodopsin-like superfamily of seven-transmembrane-spanning domain $G$-protein coupled receptors (GPCRs).

                                [ OPIOID RECEPTOR SUBTYPES ]
                                              |
        +-------------------------------------+-------------------------------------+
        |                                     |                                     |
   [ MU ($\mu$, MOR / MOP) ]             [ KAPPA ($\kappa$, KOR / KOP) ]       [ DELTA ($\delta$, DOR / DOP) ]
   - $\mu_1$: Supraspinal analgesia      - Spinal analgesia                    - Spinal & supraspinal analgesia
   - $\mu_2$: Spinal analgesia,          - Sedation, miosis                    - Modulation of mood & behavior
     respiratory depression,             - Dysphoria & hallucinations          - Mild respiratory depression
     bradycardia, constipation, miosis   - Diuresis (inhibits ADH release)     - Pro-convulsant at high doses
   - Agonists: Morphine, Fentanyl        - Agonists: Dynorphins, Nalbuphine    - Agonists: Enkephalins
   - Endogenous: $\beta$-Endorphin         - Endogenous: Dynorphins              - Endogenous: Enkephalins

Intracellular Signaling Cascade ($G_i/G_o$ Protein Coupling)

All three classical opioid receptors are coupled to pertussis toxin-sensitive inhibitory $G$-proteins ($G_{\alpha i} / G_{\alpha o}$):

                    Opioid Agonist Binds 7-TM Receptor
                                    |
                 G-protein Heterotrimer Dissociates
                                    |
        +---------------------------+---------------------------+
        |                                                       |
   [ $G_{\alpha i}$ Subunit ]                             [ $G_{\beta\gamma}$ Dimer ]
        |                                                       |
   Inhibits Adenylyl Cyclase                                    +-----------------------+
        |                                                       |                       |
   $\downarrow$ Intracellular cAMP                         [ Presynaptic ]         [ Postsynaptic ]
        |                                                  CLOSES $Ca^{2+}$         OPENS $K^+$ Channels
   $\downarrow$ Protein Kinase A (PKA)                     Channels ($N, P/Q$)     ($GIRK$ Channels)
        |                                                       |                       |
   Altered Gene Transcription                              Inhibits Exocytosis     $K^+$ Efflux Produces
   & Decreased Excitability                                of Glutamate,           Neuronal Hyperpolarization
                                                           Substance P & CGRP

1. Adenylyl Cyclase Inhibition: The active $G_{\alpha i}$ subunit inhibits adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate ($\downarrow \text{cAMP}$) and downregulating Protein Kinase A (PKA) activity.
2. Presynaptic Calcium Channel Closure: The liberated $G_{\beta\gamma}$ subunit complex directly inhibits presynaptic voltage-gated $N$-type and $P/Q$-type calcium channels. Decreased intracellular $Ca^{2+}$ influx blocks vesicular exocytosis of excitatory neurotransmitters (Substance P, glutamate, calcitonin gene-related peptide [CGRP]) from primary nociceptive afferent C and $A\delta$ fibers in the substantia gelatinosa (Rexed lamina II) of the dorsal horn.
3. Postsynaptic Potassium Channel Opening: The $G_{\beta\gamma}$ dimer activates $G$-protein coupled inward-rectifying potassium ($GIRK$) channels, triggering rapid potassium efflux. This hyperpolarizes the postsynaptic spinothalamic projection neurons, making them refractory to excitatory depolarizing stimuli.

---

2. Pharmacokinetics and Pharmacodynamics of Clinical Opioids

Morphine

• Pharmacokinetics: Low lipid solubility slows blood-brain barrier penetration; clinical analgesic onset takes 15 to 30 minutes, peaking at 45 to 60 minutes.
• Metabolism: Undergoes hepatic Phase II glucuronidation via UGT2B7 into two major metabolites:
  1. Morphine-6-Glucuronide (M6G, ~10%): Crosses the blood-brain barrier; is a more potent $\mu$-agonist than morphine (estimates range from a few-fold systemically to much higher after central administration) and contributes analgesia and respiratory depression.
  2. Morphine-3-Glucuronide (M3G, ~50-60%): Devoid of opioid analgesic activity; acts as a neurotoxin producing hyperalgesia, allodynia, myoclonus, and seizures.
• Renal Failure Hazard: Both M6G and M3G depend exclusively on renal glomerular filtration for elimination. In renal failure, M6G accumulates, causing delayed, refractory, life-threatening respiratory depression, while M3G causes severe neurotoxicity.
• Histamine Release: Stimulates mast cell degranulation, producing cutaneous flushing, pruritus, arterial hypotension, and bronchospasm.

Fentanyl and Alfentanil

• Fentanyl: Highly lipophilic phenylpiperidine derivative (100 times more potent than morphine). Rapid onset within 2 to 3 minutes. Rapid termination after a single bolus is driven entirely by redistribution from brain to muscle and fat ($t_{1/2\alpha} \approx 1-3\text{ min}$). However, after prolonged infusions, peripheral tissues saturate, causing fentanyl to leach back into the circulation and markedly prolonging its context-sensitive half-time (>250 min after a 4-hour infusion). High doses or rapid IV boluses trigger wooden chest syndrome (acute vocal cord closure and severe skeletal rigidity of the thoracic and abdominal musculature), treatable with neuromuscular blockers or naloxone.
• Alfentanil: Rapid onset (<60 seconds). Although less lipophilic than fentanyl, its low $pK_a$ of 6.5 means that at physiological blood pH of 7.4, ~90% exists in the non-ionized (free base) state. Non-ionized molecules cross the lipophilic blood-brain barrier instantaneously. Small volume of distribution ($V_d \approx 0.4-1.0\text{ L/kg}$) and high hepatic extraction via CYP3A4.

Remifentanil

• Ester Linkage: Anilinopiperidine congener possessing a chemically vulnerable methyl ester moiety on the piperidine ring.
• Metabolism: Rapidly hydrolyzed by non-specific blood and tissue esterases into remifentanil acid (GR90214), which has 1/4600th the potency of parent remifentanil. It is not metabolized by plasma pseudocholinesterase or red cell acetylcholinesterase.
• Organ Independence: Metabolism is completely independent of hepatic and renal function, patient age, or pseudocholinesterase deficiencies.
• Invariant Pharmacokinetics: Exhibits an ultra-short context-sensitive half-time of 3 to 4 minutes, which remains completely invariant regardless of whether the infusion runs for 20 minutes or 12 hours. Rapid blood-brain equilibration ($t_{1/2}k_{e0} \approx 1\text{ min}$).
• Clinical Considerations: Stopping an infusion leads to complete loss of analgesia within 5 to 10 minutes; proactive transition to longer-acting analgesics is mandatory. High-dose infusions are prone to inducing acute receptor desensitization, tolerance, and Opioid-Induced Hyperalgesia (OIH) via NMDA receptor activation.

Methadone and Tramadol

• Methadone: Racemic mixture: $R$-methadone is a potent $\mu$-agonist; $S$-methadone is a non-competitive NMDA receptor antagonist and serotonin/norepinephrine reuptake inhibitor (SNRI). Highly effective for complex neuropathic pain. High bioavailability (>80%), large volume of distribution, and a prolonged, variable elimination half-life (15 to 60+ hours). Hazard: dose-dependent blockade of cardiac delayed rectifier potassium channels ($I_{Kr}$ / hERG), causing QTc prolongation and Torsades de Pointes.
• Tramadol: Dual mechanism: weak $\mu$-agonist combined with central inhibition of noradrenaline and serotonin reuptake. Prodrug: bioactivated by hepatic CYP2D6 into $O$-desmethyltramadol (M1 metabolite), which has 200- to 300-fold higher affinity for $\mu$-receptors than parent tramadol. Poor CYP2D6 metabolizers gain inadequate analgesia, whereas ultra-rapid metabolizers risk severe respiratory depression. Lowers seizure threshold and carries high risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs.

---

3. Opioid Reversal: Naloxone

Naloxone is a pure, non-selective competitive antagonist at $\mu$, $\kappa$, and $\delta$ opioid receptors.

• Pharmacokinetics: Onset within 1 to 2 minutes IV. Duration of action is only 30 to 60 minutes (elimination half-life ~60-90 min), which is significantly shorter than the elimination half-life of morphine, hydromorphone, methadone, or transdermal fentanyl.
• Renarcotization Hazard: Once naloxone clears, persistent agonist molecules rebind to unoccupied receptors, causing recurrence of hypoventilation, coma, and apnea. Patients must be monitored continuously for at least 2 to 4 hours post-reversal, and a continuous naloxone infusion (dosed at two-thirds of the initial successful bolus per hour) may be required.
• Acute Sympathetic Surge: Over-rapid or excessive naloxone administration abruptly strips both exogenous and endogenous opioids from receptors. This produces an intense surge of endogenous catecholamines, precipitating excruciating pain, severe hypertension, tachycardia, ventricular arrhythmias, myocardial infarction, and acute non-cardiogenic pulmonary edema. Naloxone must be titrated in small aliquots (20 to 40 $\mu\text{g}$ every 2 to 3 minutes) until spontaneous ventilation returns without completely reversing analgesia.

---

4. Non-Opioid Analgesic Agents

Paracetamol (Acetaminophen)

• Mechanism of Action: Central inhibition of prostaglandin synthesis through selective inhibition of the peroxidase catalytic activity of cyclooxygenase enzymes (COX-1 and COX-2) in cellular environments with low peroxide concentrations (such as the brain). Devoid of peripheral anti-inflammatory activity because high lipid peroxide concentrations in inflamed peripheral tissues inactivate paracetamol. Modulates descending serotonergic inhibitory pathways and the endocannabinoid system (metabolized to AM404, which inhibits cellular reuptake of anandamide).
• Dosing and Limits: Maximum dose is $4\text{ g/day}$ ($1\text{ g}$ every 6 hours) in healthy adults; reduced to $\le 2-3\text{ g/day}$ in chronic alcoholism, malnutrition, low body weight (<50 kg), or preexisting liver disease.
• Overdose and Hepatotoxicity Pathophysiology:

                                  Paracetamol Ingestion
                                            |
        +-----------------------------------+-----------------------------------+
        | (90% - Normal Therapeutic Pathways)                                    | (5-10% - Toxic Pathway)
        v                                                                       v
  Hepatic Glucuronidation & Sulfation                                     CYP2E1 Oxidation
  (Saturated in Overdose)                                                       |
        |                                                                       v
  Non-toxic Urinary Conjugates                                              [ NAPQI ]
                                                                   (Highly Toxic Electrophile)
                                                                                |
                                            +-----------------------------------+-----------------------------------+
                                            | (Glutathione Stores Normal)                                           | (Glutathione Depleted by >70%)
                                            v                                                                       v
                                      Glutathione Conjugate                                                   NAPQI Binds Hepatocyte Proteins
                                      (Mercapturic Acid - Non-toxic)                                          Mitochondrial Permeability Transition
                                                                                                              Centrilobular Hepatic Necrosis

• Antidote: $N$-Acetylcysteine (NAC). Acts as a cysteine precursor to replenish depleted intracellular hepatic glutathione stores and directly conjugates free NAPQI as a glutathione substitute. Most effective when administered within 8 hours of acute ingestion.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Mechanism: Inhibit cyclooxygenase (prostaglandin $H_2$ synthase), halting the conversion of arachidonic acid into pro-inflammatory prostaglandins ($PGE_2, PGI_2$) and thromboxane $A_2$ ($TXA_2$):
  • Non-selective COX Inhibitors: Ibuprofen, ketorolac, diclofenac, naproxen (inhibit both COX-1 and COX-2).
  • Selective COX-2 Inhibitors: Celecoxib, parecoxib, etoricoxib (sparing COX-1).
• Organ System Toxicities:
  1. Gastrointestinal Ulceration: COX-1 inhibition suppresses mucosal synthesis of cytoprotective $PGE_2$ and $PGI_2$ (which normally stimulate gastric mucus and bicarbonate secretion while maintaining mucosal blood flow), leading to peptic ulceration and life-threatening gastrointestinal hemorrhage.
  2. Renal Dysfunction and Acute Kidney Injury (AKI): In states of decreased effective circulating volume (hypovolemia, congestive heart failure, sepsis, cirrhosis), renal perfusion is critically maintained by vasodilatory prostaglandins ($PGE_2, PGI_2$) that dilate the afferent glomerular arteriole. NSAID administration uncouples this compensatory mechanism, triggering severe afferent arteriolar vasoconstriction, sharp drops in glomerular filtration rate (GFR), and acute tubular necrosis.
  3. Platelet Dysfunction: Non-selective NSAIDs block platelet COX-1, halting synthesis of thromboxane $A_2$ ($TXA_2$) and impairing platelet aggregation. Aspirin binds irreversibly via acetylation (persisting for the 7- to 10-day lifespan of the platelet); traditional NSAIDs bind reversibly. Selective COX-2 inhibitors spare platelet COX-1 and do not impair primary hemostasis; however, by suppressing endothelial prostacyclin ($PGI_2$, a vasodilator and platelet inhibitor) while leaving platelet $TXA_2$ unchecked, selective COX-2 inhibitors create a pro-thrombotic state that increases myocardial infarction and stroke risks.
  4. Bronchospasm in AERD: In Aspirin-Exacerbated Respiratory Disease (Samter's triad: asthma, chronic rhinosinusitis with nasal polyps, and aspirin sensitivity), COX inhibition shunts arachidonic acid into the 5-lipoxygenase (5-LOX) pathway. This drives massive overproduction of cysteinyl leukotrienes ($LTC_4, LTD_4, LTE_4$), triggering severe, life-threatening bronchospasm.

Gabapentinoids: Gabapentin and Pregabalin

• Structure and Target: Structural analogs of $\gamma$-aminobutyric acid that do not bind to $GABA_A$ or $GABA_B$ receptors, nor do they alter GABA synthesis or reuptake.
• Mechanism: Bind selectively to the auxiliary $\alpha_2\delta-1$ and $\alpha_2\delta-2$ subunits of presynaptic voltage-gated calcium channels in the dorsal horn of the spinal cord. Binding inhibits forward trafficking of calcium channels to the presynaptic terminal membrane, reducing calcium influx upon nerve depolarization. This downregulates the exocytotic release of excitatory neurotransmitters (glutamate, Substance P, CGRP), dampening central sensitization and hyperalgesia.
• Clinical Indications: First-line treatment for chronic neuropathic pain (post-herpetic neuralgia, diabetic neuropathy) and key components of opioid-sparing perioperative multimodal analgesia protocols.
• Pharmacokinetics and Toxicity: Excreted 100% unchanged in urine by glomerular filtration; doses must be reduced in renal impairment. Primary adverse effects include dose-dependent sedation, dizziness, ataxia, peripheral edema, and synergistic respiratory depression when co-administered with opioids.